Last checked at 30 Apr 2018 07:00
30 April 2018 | AIM: RENE |
ReNeuron Group plc
("ReNeuron" or the "Company")
Capital Markets Event and Webcast
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it will be hosting a capital markets event on the Company's exosome nanomedicine platform on Thursday 17 May 2018. The event, for analysts and institutional investors, will take place at 2.30pm at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
ReNeuron is a leader in the field of exosomes; this event will provide an opportunity for attendees to learn more about the continued progress being made in the Company's exosome programme, which is based on exosomes secreted by the Company's proprietary CTX stem cell line.
The event will be hosted by Olav Hellebø, CEO of ReNeuron, and will include presentations by Dr Randolph Corteling, the Company's Head of Research, and Dr Stephen J Gould, a key opinion leader from the Johns Hopkins School of Medicine, Baltimore, Maryland. Dr Gould is a professor of biological chemistry, has published more than 100 scientific papers, and serves as the president of the American Society of Exosomes and Microvesicles.
The Company will not be providing any new material information.
Webcast details
To access a webcast of the event, please log on to the following web address approximately 10 minutes before 2.30pm on the day of the event:
http://vm.buchanan.uk.com/2018/reneuron170518/registration.htm
A recording of the presentation will be made available on ReNeuron's website, www.reneuron.com.
ENDS
ENQUIRIES:
ReNeuron | +44 (0)20 3819 8400 |
Olav Hellebø , Chief Executive Officer | |
Michael Hunt, Chief Financial Officer | |
Buchanan | +44 (0) 20 7466 5000 |
Mark Court, Sophie Wills, Stephanie Watson | |
Stifel Nicolaus Europe Limited | +44 (0) 20 7710 7600 |
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) | |
N+1 Singer Advisory LLP | +44 (0) 20 7496 3000 |
Mark Taylor (Joint Broker) |
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.